Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
ImmunoGen revenue increased from $82.3 million in 2019 to $132.3 million in 2020, a (60.8%) increase.

Annual Revenue ($)

ImmunoGen revenue was $132.3 m in FY, 2020 which is a (60.8%) year over year increase from the previous period.

Quarterly Revenue ($)

FY, 2018FY, 2019FY, 2020
Revenue$53.45 m$82.27 m$132.3 m
Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021
Revenue$8.58 m$15.54 m$13.28 m$13.29 m$15.03 m$18.19 m$15.71 m

Annual Growth Rate (%)

Revenue Breakdown

Business Segment

ImmunoGen revenue breakdown by business segment: 51.8% from Non-Cash Royalty Revenue, 48.2% from License and Milestone Fees and 0.0% from Other

FY, 2019FY, 2020FY, 2018
Non-Cash Royalty Revenue$47.42 m$68.53 m$32.15 m
License and Milestone Fees$34.79 m$63.74 m$15.28 m
Clinical Materials Revenue$4.64 m
Research and Development Support$68 k$28 k$1.38 m

Need Data?

Craft can deliver 250+ data points of financial, operating, and human capital indicators on companies via API.

Footer menu